本文源自：金融界AI电报 脑动极光-B(06681.HK)公告，公司与丝路之舟科技有限公司订立战略合作协议，双方将在马来西亚及东 南亚区域围绕认知障碍数字疗法产品的本土化落地、市场推广与科研转化等领域开展深度战略合作，共 同推动数字健康产业发展。根据协议，双方合作包括专项实验室建设：丝路之舟协助本公司在马来西亚 设立"认知障碍数字疗法专项实验室"，协调当地审批、场地规划及设备进口等事宜；本公司提供技术方 案与科研支持，主导研发与运营等。 ...

格隆汇2月5日丨脑动极光-B(06681.HK)宣布，公司与丝路之舟科技有限公司("丝路之舟")订立战略合作 协议，双方将在马来西亚及东南亚区域围绕认知障碍数字疗法产品的本土化落地、市场推广与科研转化 等领域开展深度战略合作，共同推动数字健康产业发展。 根据协议，双方合作主要包括以下内容： (V)东南亚市场开拓合作：以马来西亚合作为基础，逐步拓展至印尼、泰国、越南等其他东南亚国家。 协议为双方就马来西亚及东南亚市场合作订立的框架协议，後续具体执行细节将由双方进一步约定实施 细则。 董事会相信，此次合作将为公司带来长期发展机遇，为股东创造可持续价值，具体而言： (I)深化国际化布局，拓展海外市场：公司已先後在中国香港、澳门及新加坡开展业务推广及运营，积累 海外市场经验。本次与丝路之舟合作，标志着公司正式进入马来西亚市场，进一步拓展东南亚业务网 络，有助于将公司在中国市场验证的数字疗法经验与技术体系系统性地输出至具备成长潜力与政策支持 的区域市场，进一步扩大公司在国际上的品牌影响力与业务覆盖，提升全球影响力。 (II)借助本地资源，加速市场落地：丝路之舟在马来西亚拥有丰富的政府与医疗资源网络，可协助公司 高效完成 ...

于配售事项及先旧后新认购事项完成后，经扣除所有相关费用、成本及开支的所得款项净额总额估计约 为500.68百万港元。公司拟将先旧后新认购事项之所得款项净额用于下列事项：(a)为研发计划拨付资 金；(b)国内及国际市场开发；(c)战略投资及收购；及(d)补充公司及其附属公司作一般公司用途的营运 资金。 由于完成先旧后新认购事项的所有条件已达成，公司于2026年2月5日根据配售及认购协议的条款及条件 按每股先旧後新认购股份5.6港元向卖方配发及发行9200万股先旧後新认购股份。 格隆汇2月5日丨脑动极光-B(06681.HK)布，配售事项已根据配售及认购协议的条款及条件于2026年1月 27日完成，配售代理按尽力基准成功按配售价每股配售股份5.6港元向不少于六名承配人配售合共9200 万股配售股份。 ...

BrainAurora Medical Technology Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6681） 自願公告 訂立戰略合作協議以拓展馬來西亞市場及深化國際化布局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發布的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣布，本公司與絲路之舟科技有限公司（「絲路之 舟」）訂立戰略合作協議（「協議」），雙方將在馬來西亞及東南亞區域圍繞認知障礙 數字療法產品的本土化落地、市場推廣與科研轉化等領域開展深度戰略合作，共 同推動數字健康產業發展。 合作背景與內容 馬來西亞為東南亞重要經濟體之一，正面臨快速人口老化及精神健康需求攀升 的挑戰。根據馬來西亞統計局數據，2023年該國60歲以上人口達380萬。與此同 時，青少年心理健康問題亦日益突出。馬來西亞政府雖已推動多項精神健康政 策，然診療資源仍顯稀 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 完成 根據一般授權配售現有股份及先舊後新認購新股份 獨家整體協調人、配售代理及資本市場中介機構 完成配售事項及先舊後新認購事項 董事會欣然宣佈，配售事項已根據配售及認購協議的條款及條件於2026年1月27 日完成，配售代理按盡力基準成功按配售價每股配售股份5.6港元向不少於六(6) 名承配人配售合共92,000,000股配售股份。據董事經作出一切合理查詢後所深 知、盡悉及確信，承配人及其最終實益擁有人均為獨立第三方。 由於完成先舊後新認購事項的所有條件已達成，本公司於2026年2月5日根據配 售及認購協議的條款及條件按每股先舊後新認購股份5.6港元向賣方配發及發行 92, ...

致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000,000 | USD | 0.0000001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 ...

Group 1 - A total of 78 stocks reached a 52-week high as of February 3, with notable performers including Asia Pacific Financial Investments (08193) at 57.14%, Chao Wei Holdings (08059) at 36.00%, and Asia Backup (08290) at 33.33% [1] - The closing prices for the top three stocks that reached new highs were 0.550, 0.052, and 0.024 respectively, with their highest prices being 0.550, 0.068, and 0.036 [1] - Other significant stocks that reached new highs include Huameilele (08429) with a high rate of 20.37% and Haode Holdings (08149) at 17.65% [1] Group 2 - The report also lists stocks that reached 52-week lows, with the worst performer being Gaodi Holdings (01676) at -10.00%, followed by Huajian Medical (01931) at -9.29% and Electronic Trading Group (08036) at -9.09% [3] - The closing prices for the stocks that reached new lows include 0.340, 1.280, and 0.021 respectively, with their lowest prices being 0.315, 1.270, and 0.020 [3] - Other notable stocks that reached new lows include Controllon (01912) at -8.93% and Cool Link (08491) at -8.11% [3]

Core Viewpoint - The article discusses a significant quality dispute in the domestic power battery industry, highlighting the lawsuit filed by Weir against XWANDA for 2.3 billion yuan due to battery quality issues, which raises concerns about the implications for automakers who develop their own battery packs [4][6][26]. Group 1: Lawsuit Details - Weir has sued XWANDA for 2.3 billion yuan, claiming that the battery cells supplied by XWANDA from June 2021 to December 2023 had quality issues [4]. - The lawsuit stems from problems with the Zeekr 001 WE86 version, which experienced slow charging and abnormal battery degradation [5][6]. - XWANDA argues that the issues are due to Weir's aggressive charging strategies and modifications to battery usage conditions, not the quality of the cells themselves [6][7]. Group 2: Financial Implications - If Weir wins the lawsuit, XWANDA could face a loss equivalent to approximately two years of net profit, as their projected net profits for 2022 to Q1 2025 are 1.068 billion, 1.076 billion, 1.468 billion, and 386 million yuan respectively [6][7]. - The lawsuit not only poses a financial threat but also risks damaging XWANDA's reputation among customers, potentially affecting future business opportunities [7]. Group 3: Industry Trends - The dispute highlights the risks associated with automakers developing their own battery packs, as seen with companies like Leap Motor, Li Auto, and Xiaomi, which have sought to reduce reliance on major battery suppliers [7][24]. - The trend towards self-manufactured battery packs aims to lower costs and enhance product quality control, but the lawsuit illustrates the complexities and potential liabilities that can arise from this approach [24][26]. Group 4: Technical Considerations - The core issue in the dispute revolves around the responsibility for battery pack quality, specifically the roles of the battery cells and Battery Management System (BMS) [9][15]. - Variability in battery cell production can lead to quality differences, complicating accountability when issues arise [11][27]. - The BMS plays a crucial role in battery performance, and its strategies can significantly impact the longevity and efficiency of the battery pack [15][18]. Group 5: Future Outlook - Despite the challenges highlighted by the lawsuit, the trend towards self-manufactured battery packs is expected to continue as automakers seek greater control over supply chain safety and cost management [35].

Core Viewpoint - The lawsuit involving a 2.3 billion yuan claim against Xiwanda by Weirui highlights significant quality disputes in the domestic power battery industry, particularly concerning the battery cells supplied by Xiwanda to Weirui for the Zeekr 001 WE86 model, which experienced issues such as slow charging and abnormal battery degradation [1][2][3]. Summary by Sections Legal Dispute - Weirui claims that the quality issues with the battery cells supplied by Xiwanda led to costs for battery replacements and damage to the Zeekr brand image, thus seeking 2.3 billion yuan in compensation [2]. - Xiwanda argues that Weirui's aggressive charging strategy and "lock battery" operations altered the usage conditions of the batteries, which contributed to the problems [2]. Financial Impact - The potential loss of 2.3 billion yuan in compensation could equate to approximately two years of net profit for Xiwanda, which reported net profits of 1.068 billion, 1.076 billion, 1.468 billion, and 386 million yuan from 2022 to Q1 2025 [2]. - The lawsuit has negatively impacted Xiwanda's corporate image among end consumers, leading to a cautious stance from potential clients [2]. Industry Implications - The dispute underscores the risks associated with automakers developing their own battery packs and the complexities of determining responsibility for battery quality issues [3][4]. - The trend of automakers like Leap Motor, Li Auto, and Xiaomi to self-develop battery packs and BMS systems to reduce reliance on major battery suppliers is now facing scrutiny due to this legal case [3][13]. Technical Aspects - The core controversy revolves around the responsibility for battery pack quality issues, specifically between the battery cells and the Battery Management System (BMS) [4]. - Variability in battery cell quality between different production batches can lead to significant performance differences, complicating quality assurance [5][6]. - The design and control of battery cells, particularly in terms of manufacturing consistency, are critical to ensuring performance and longevity [5][6]. Future Trends - Despite the challenges highlighted by the lawsuit, the trend towards self-manufactured battery packs is expected to continue as automakers seek greater control over costs and product quality [19]. - The complexities of determining liability in battery quality disputes may lead to more collaborative approaches between automakers and battery manufacturers to mitigate risks [19].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 下列責任聲明應載於該公告之末： BrainAurora Medical Technology Limited 「全體董事願就本公告所載資料的準確性共同及個別承擔全部責任，並在作出一切 合理查詢後確認，就彼等所深知，本公告所表達的意見乃經審慎周詳考慮後始行 作出，且本公告並無遺漏任何其他事實，致使本公告任何陳述產生誤導。」 腦動極光醫療科技有限公司 除上文所述外，該公告所載其他資料維持不變。 （於開曼群島註冊成立的有限公司） （股份代號：6681） 澄清公告 茲提述本公司日期為2026年1月23日的公告（「該公告」），內容有關（其中包括）配 售事項及先舊後新認購事項。除另有界定外，本公告所用詞彙與該公告所界定者 具有相同涵義。 譚錚先生 主席兼執行董事 香港，2026年1月27日 截至本公告日期，董事會包括：(i)執行董事譚錚先生； ...